Tardieu, M.

sclerosis treatment patient relapse relapse rate therapy study erasmus univ rotterdam neurology disease children adult ped-m neurol interferon paediatric natalizumab ghezzi disability trial safety e fficacy ped-ms patients rotterdam side e ffects lesion relapsing onset erasmu adolescent reaction disease progression department treatment failure activity evidence interferon beta -1b injection result month msj.sagepub.com effect medication failure antibody downloaded symptom reduction sclerosis patients university relapsing –remitting fficacy lancet scler progression impact response attack management immunomodulatory treatment fi rst placebo-controlled trial neutralizing antibodies event duration e ffective cyclophosphamide banwell group population liver hospital childhood first-line disease-modifying therapies resonance imaging syndrome fi rst attack fatigue european rebif